Market Overview

JP Morgan Comments on Wet AMD Data for Regeneron


JP Morgan has published a research report on Regeneron Pharmaceuticals (NASDAQ: REGN) after wet AMD data was released on the company's Lucentis and Opththotech's Fovista.

In the report, JP Morgan writes, "Today, competitive data in the wet AMD (Age-related Macular Degeneration) space was released on the combination of Lucentis and Ophthotech's Fovista (aka E10030). In a large phase 2b study in 449 wet AMD patients, Lucentis + Fovista showed a 62% increase in visual outcome relative to Lucentis alone. Specifically, patients on the combo (1.5 mg Fovista) gained 10.6 letters versus 6.5 letters for Lucentis alone (p=0.019) in only 6 months, and importantly, visual outcome improved every month of the study. A statistically significant treatment effect on vision on top of a standard of care is very differentiated in the wet AMD space, in our view. Fovista (PDGF-inhibitor) could be synergistic with other anti-VEGF therapies (Avastin and Eylea), however there is a longer-term relationship with Roche in place and Fovista has only been tested in phase 1 and 2 studies with Roche's Lucentis. In our view, the phase 2 significantly de-risks a phase 3 trial and it highlights the potential for a new paradigm in wet AMD. Given concerns on 2012 Eylea expectations (JPMe: $550M; cons: ~$610M) and the risk of moderating Eylea demand, combined with longer-term concerns over the competitive landscape, we are maintaining our Neutral rating on REGN shares."

JP Morgan maintains its Neutral rating on Regeneron Pharmaceuticals, which is currently trading down $6.84 form yesterday's $127.85 closing price.

Latest Ratings for REGN

Nov 2020Morgan StanleyMaintainsEqual-Weight
Nov 2020Credit SuisseMaintainsOutperform
Nov 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings


Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: Fovista JP Morgan LucentisAnalyst Color Reiteration Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at